<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20031101//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3316545</article-id><article-id pub-id-type="pmid">22479341</article-id><article-id pub-id-type="publisher-id">PONE-D-11-10042</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0032802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Enzyme Classes</subject></subj-group></subj-group><subj-group><subject>Proteins</subject></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Oncology</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">Phosphatase</z:uniprot> 1 Dephosphorylates <z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">Profilin-1</z:uniprot> at Ser-137 </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Dephosphorylation of Profilin-1 by PP1</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shao</surname><given-names>Jieya</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Diamond</surname><given-names>Marc I.</given-names></name></contrib></contrib-group><aff id="aff1">
<addr-line>Department of Neurology, School of Medicine, Washington University, St. Louis, Missouri, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>El-Rifai</surname><given-names>Wael</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Vanderbilt University Medical Center, United States of America</aff><author-notes><corresp id="cor1">* E-mail: <email>shaoj@neuro.wustl.edu</email></corresp><fn fn-type="con"><p><text><SENT sid="1" pm="."><plain>Conceived and designed the experiments: JS MID. </plain></SENT>
<SENT sid="2" pm="."><plain>Performed the experiments: JS. </plain></SENT>
<SENT sid="3" pm="."><plain>Analyzed the data: JS MID. </plain></SENT>
<SENT sid="4" pm="."><plain>Contributed reagents/materials/analysis tools: JS MID. </plain></SENT>
<SENT sid="5" pm="."><plain>Wrote the paper: JS MID. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2012</year></pub-date><volume>7</volume><issue>3</issue><elocation-id>e32802</elocation-id><history><date date-type="received"><day>5</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>Shao, Diamond.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">Profilin-1</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>) plays an important role in the control of <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> dynamics, and could represent an important therapeutic target in several diseases. </plain></SENT>
<SENT sid="7" pm="."><plain>We previously identified <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> as a <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot> aggregation inhibitor, and others have implicated it as a tumor-suppressor. </plain></SENT>
<SENT sid="8" pm="."><plain>Rho-associated kinase (ROCK) directly phosphorylates <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137 to prevent its binding to polyproline sequences. </plain></SENT>
<SENT sid="9" pm="."><plain>This negatively regulates its anti-aggregation activity. </plain></SENT>
<SENT sid="10" pm="."><plain>However, the <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> that dephosphorylates <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137, and thus activates it, is unknown. </plain></SENT>
<SENT sid="11" pm="."><plain>Using a phospho-specific antibody against Ser-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, we characterized <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> dephosphorylation in cultured cells based on immunocytochemistry and a quantitative plate reader-based assay. </plain></SENT>
<SENT sid="12" pm="."><plain>Both okadaic acid and endothall increased pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels at concentrations more consistent with their known IC50s for protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 1 (<z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>) than protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 2A (<z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot>). </plain></SENT>
<SENT sid="13" pm="."><plain>Knockdown of the catalytic subunit of <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (PP1Cα), but not <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (PP2ACα), increased pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. </plain></SENT>
<SENT sid="14" pm="."><plain>PP1Cα binds <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in cultured cells, and this interaction was increased by a phosphomimetic mutation of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137 (S137D). </plain></SENT>
<SENT sid="15" pm="."><plain>Together, these data define <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> as the principal <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> for Ser-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, and provide mechanistic insights into <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> regulation by phosphorylation. </plain></SENT>
</text></SecTag></p></abstract><counts><page-count count="8"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="16" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">Profilins</z:uniprot> are small <z:uniprot sup="inside" fb="0" ids="P38479,P15891">actin-binding proteins</z:uniprot> that are essential for all eukaryotic cells. </plain></SENT>
<SENT sid="18" pm="."><plain>They play a role in many cellular processes including cell motility, cytokinesis, gene transcription, endocytosis and neuronal plasticity [1], [2], [3], [4]. </plain></SENT>
<SENT sid="19" pm="."><plain>These activities depend on their interactions with three major cellular ligands: globular <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> (G-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot>), polyproline-containing proteins, and phosphatidylinositols (e.g. phosphatidylinositol 4,5-bisphosphate, <z:uniprot sup="inside" fb="0" ids="F4JRC5,P52960,P52488">PIP2</z:uniprot>). </plain></SENT>
<SENT sid="20" pm="."><plain>In mammals, four <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> isoforms have been identified, each encoded by a distinct gene. </plain></SENT>
<SENT sid="21" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">Profilin-1</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>) and <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot>-2a (PFN2a), the classic “somatic” isoforms, are 65% identical in amino acid sequence, and highly conserved in 3D structure [3]. </plain></SENT>
<SENT sid="22" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> is ubiquitously expressed, while PFN2a, the major splice isoform of <z:uniprot sup="inside" fb="0" ids="Q42418,Q09430,P35080,Q4R4P8,Q5R4E2">PFN2</z:uniprot>, is preferentially enriched in the brain [3]. </plain></SENT>
<SENT sid="23" pm="."><plain>Two <z:uniprot sup="inside" fb="0" ids="P08070">testis-specific</z:uniprot> <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilins</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q38904,Q32PB1,P60673">PFN3</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q2NKT1,Q8NHR9">PFN4</z:uniprot>, are recently described, and differ substantially from <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> and PFN2a in their primary sequences [5]. </plain></SENT>
<SENT sid="24" pm="."><plain>Both <z:uniprot sup="inside" fb="0" ids="Q38904,Q32PB1,P60673">PFN3</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q2NKT1,Q8NHR9">PFN4</z:uniprot> bind G-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> with lower affinity than <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> and PFN2a. </plain></SENT>
<SENT sid="25" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q38904,Q32PB1,P60673">PFN3</z:uniprot> binds polyproline-ligands poorly, and <z:uniprot sup="inside" fb="0" ids="Q2NKT1,Q8NHR9">PFN4</z:uniprot> completely lacks this activity [5]. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Recent studies have linked <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilins</z:uniprot>, in particular <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, to several human diseases. </plain></SENT>
<SENT sid="27" pm="."><plain>Our prior work identified <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> as an inhibitor of <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot> aggregation, suggesting a role in the pathogenesis of Huntington Disease (HD). </plain></SENT>
<SENT sid="28" pm="."><plain>The anti-aggregation activity of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> depends on its binding to both G-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> and a polyproline tract within <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot> [6]. </plain></SENT>
<SENT sid="29" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> is also a putative tumor suppressor, and has been shown to inhibit tumor cell growth and metastasis in several cancer models [7], [8], [9], [10], [11], [12]. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Despite our detailed knowledge of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot>'s structure and functions, we know little about how its cellular activities are regulated. </plain></SENT>
<SENT sid="31" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> is a phospho-protein in vivo [13], [14], suggesting that its activities could be regulated by phosphorylation. </plain></SENT>
<SENT sid="32" pm="."><plain>We have previously determined that Ser-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> is a bona fide phosphorylation site for the Rho-associated kinase ROCK [6]. </plain></SENT>
<SENT sid="33" pm="."><plain>Ser-137 lies within the polyproline-binding site of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="34" pm="."><plain>Mimicking phosphorylation at this site abolishes <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s binding to <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot>, and inhibits its activity as an aggregation suppressor [6]. </plain></SENT>
<SENT sid="35" pm="."><plain>To our knowledge, this was the first study to link a specific phosphorylation event to defined cellular functions of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, and to demonstrate that <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> activity is regulated. </plain></SENT>
<SENT sid="36" pm="."><plain>While our prior work identified ROCK as an upstream kinase for Ser-137, it left uncertain which <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> mediates dephosphorylation of this site. </plain></SENT>
<SENT sid="37" pm="."><plain>By exploiting a highly sensitive and specific <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibody against pSer-137, we now provide pharmacological, genetic and biochemical evidence that protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot>-1 (<z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>) exists in the same protein complex with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> and dephosphorylates Ser-137. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="38" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="39" pm="."><plain>P3490 specifically recognizes pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in situ </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>We previously generated a polyclonal phospho-specific antibody against pSer-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (P3490). </plain></SENT>
<SENT sid="41" pm="."><plain>Using this antibody, we previously determined by Western blot (WB) that pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels in cultured cells are regulated by RhoA/ROCK signaling. </plain></SENT>
<SENT sid="42" pm="."><plain>The RhoA activator lysophosphatidic acid (<z:uniprot sup="inside" fb="8" ids="P08519,P14417,Q84R36">LPA</z:uniprot>) mildly increased pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels in cultured cells, which was blocked by the ROCK inhibitor Y-27632 [6]. </plain></SENT>
<SENT sid="43" pm="."><plain>To directly characterize the phospho-specificity of this antibody, we pre-incubated P3490 with antigenic peptides containing (pS137) or lacking a phosphate on Ser-137 (S137), followed by WB to determine if its reactivity with cellular <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> was affected. </plain></SENT>
<SENT sid="44" pm="."><plain>The pS137-peptide completely blocked P3490 binding to <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (Fig. 1A) as expected. </plain></SENT>
<SENT sid="45" pm="."><plain>However, the non-phospho S137-peptide effectively blocked 90% of the <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> signal versus the no peptide control (Fig. 1A). </plain></SENT>
<SENT sid="46" pm="."><plain>Thus, P3490 contains pan-antibodies that react with unphosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, and the bulk of the observed <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> signal likely represents cross-reactivity with unphosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> molecules that outnumber those of phospho-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="47" pm="."><plain>This limits the fidelity of P3490 to accurately report pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels via WB. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0032802-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032802.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="48" pm="."><plain>In situ staining of mammalian cells by pSer-137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibody P3490 is responsive to RhoA/ROCK signaling. </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>A, Equal amounts of HEK293 cell lysate were separated on SDS-PAGE, and individual lanes were blotted with P3490 that was pre-incubated with no peptide (Lane 1), or <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> peptides containing unphosphorylated (Lane 2) or phosphorylated Ser-137 (Lane 3). </plain></SENT>
<SENT sid="50" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-pS137 peptide completely blocked the binding of P3490 to <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="51" pm="."><plain>Unphosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-S137 peptide blocked ∼90% binding vs. the no peptide control. </plain></SENT>
<SENT sid="52" pm="."><plain>Total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (on a separate and identically loaded gel) and <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> levels were confirmed as being equal across all lanes. B, P3490 stains the cytoplasm of multiple cell lines in a heterogeneous fashion, including HEK293, HeLa and NIH 3T3 (in green). </plain></SENT>
<SENT sid="53" pm="."><plain>DAPI was used as counterstain (in blue). C, Immunostaining of HEK293 cells with P3490 (green) was unaffected by pre-incubation with the unphosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-S137 peptide, but was completely inhibited by the phosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-pS137 peptide. </plain></SENT>
<SENT sid="54" pm="."><plain>DAPI staining is shown in blue. D, NIH 3T3 cells were serum-starved for 16 hr in the absence or presence of 50 µM Y-27632, followed by treatment with 10 µM Lysophosphatidic acid (<z:uniprot sup="inside" fb="8" ids="P08519,P14417,Q84R36">LPA</z:uniprot>) for 60 min. </plain></SENT>
<SENT sid="55" pm="."><plain>Cells were immunostained with P3490 (green) and counterstained with DAPI (blue) (a–c). </plain></SENT>
<SENT sid="56" pm="."><plain><z:uniprot sup="inside" fb="8" ids="P08519,P14417,Q84R36">LPA</z:uniprot> increased P3490 staining, which was blocked by the pretreatment with Y-27632. </plain></SENT>
<SENT sid="57" pm="."><plain>Total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels were unaffected by these treatments as indicated by immunostaining with a generic <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibody (<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in green and DAPI in blue) (d–l). E, HEK293 cells were treated with or without 50 µM hydroxyfasudil (OH-fasudil) for 2 hr, followed by immunostaining with P3490 (a–b) or the generic <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibody (c–d) (both in green) and counterstaining with DAPI (blue). </plain></SENT>
<SENT sid="58" pm="."><plain>Nearly all cells treated with OH-fasudil became P3490-negative without changes in their total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. F, HEK293 cells grown in a 96-well plate were treated for 24 hr with increasing concentrations of OH-fasudil (1, 3, 10, 50 µM), immunostained with P3490 and Alexa Fluor®488-labeled secondary antibody, and counterstained with DAPI. </plain></SENT>
<SENT sid="59" pm="."><plain>Fluorescence intensity was quantified on a fluorescence plate reader. </plain></SENT>
<SENT sid="60" pm="."><plain>P3490 staining was normalized vs. DAPI to control for cell numbers, and the effects of OH-fasudil were calculated as relative values as compared to the untreated cells. </plain></SENT>
<SENT sid="61" pm="."><plain>OH-fasudil reduced P3490 staining dose-dependently. </plain></SENT>
<SENT sid="62" pm="."><plain>Error bars represent the standard error of the mean (SEM). </plain></SENT>
<SENT sid="63" pm="."><plain>Data are mean ± SEM of three independent experiments. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0032802.g001"/></fig></SecTag><p><text><SENT sid="64" pm="."><plain>Due to the limitation of P3490 associated with WB, we tested if it can detect pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in situ by immunocytochemistry. </plain></SENT>
<SENT sid="65" pm="."><plain>P3490 heterogeneously stained several cell lines (predominantly the cytoplasm), i.e. not all cells were positive at the same time (Fig. 1B). </plain></SENT>
<SENT sid="66" pm="."><plain>The cause for this staining pattern of P3490 is unclear, but could either reflect individual variation among cells, or cell cycle dependence. </plain></SENT>
<SENT sid="67" pm="."><plain>Cell staining by P3490 was completely inhibited by its pre-incubation with the pS137-peptide, but was unaffected by the unphosphorylated S137-peptide (Fig. 1C). </plain></SENT>
<SENT sid="68" pm="."><plain>This contrasted the results on WB, and suggested that P3490 is highly phospho-specific when used for in situ cell staining, in which the pan-antibodies are nonreactive. </plain></SENT>
<SENT sid="69" pm="."><plain>In serum-starved NIH 3T3 cells, the RhoA activator lysophosphatidic acid (<z:uniprot sup="inside" fb="8" ids="P08519,P14417,Q84R36">LPA</z:uniprot>) markedly increased the number of P3490-positive cells, and this was blocked by ROCK inhibition with Y-27632 (Fig. 1D). </plain></SENT>
<SENT sid="70" pm="."><plain>Hydroxyfasudil (OH-fasudil), a ROCK inhibitor structurally distinct from Y-27632, also dose-dependently reduced P3490 staining. </plain></SENT>
<SENT sid="71" pm="."><plain>These effects were visible microscopically (Fig. 1E), and easily quantified using a fluorescence plate reader following incubation with a fluorescently-labeled (Alexa Fluor®488) secondary antibody (Fig. 1F). </plain></SENT>
<SENT sid="72" pm="."><plain>At 50 µM, OH-fasudil eliminated P3490 staining in nearly all cells without affecting their total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels (Fig. 1E). </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>We further confirmed the specificity of P3490 for pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> using RNAi knockdown of endogenous <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="74" pm="."><plain>HEK293 cells were transduced with lentiviral shRNAs targeting <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (Fig. 2A), which reduced P3490 staining (Fig. 2B–C), consistent with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> being the cellular target of the antibody. </plain></SENT>
<SENT sid="75" pm="."><plain>This effect was evident microscopically (Fig. 2B), and was quantified using the fluorescence plate reader (Fig. 2C). </plain></SENT>
<SENT sid="76" pm="."><plain>The relative decrease in total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> level (60%) as a result of shRNA knockdown was larger than that of P3490 staining (40%). </plain></SENT>
<SENT sid="77" pm="."><plain>This implies that Ser-137 phosphorylation of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> may need to be kept at a certain level in the cell, and could be regulated in a fashion partially independent of total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. </plain></SENT>
<SENT sid="78" pm="."><plain>In addition, P3490 stained ectopically expressed phosphomimetic <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) in cultured cells, but not <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt) or <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A). </plain></SENT>
<SENT sid="79" pm="."><plain>This was most evident when phosphorylation of endogenous <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137 was inhibited by OH-fasudil (Fig. 2D), and was also quantified by the fluorescence plate reader (Fig. 2E and F). </plain></SENT>
<SENT sid="80" pm="."><plain>Taken together, these results confirmed the specificity of P3490 for pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> for in situ staining. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0032802-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032802.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="81" pm="."><plain>P3490 specifically detects pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> via immunofluorescence staining. </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>A, HEK293 cells were infected for three days with lentiviral shRNA particles encoding either a scrambled nucleotide sequence (Ctrl shRNA), or a target-specific sequence for human <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> shRNA). </plain></SENT>
<SENT sid="83" pm="."><plain>Efficient <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> knockdown was confirmed by Western blot. B, virus-mediated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> knockdown reduced P3490 staining (green, a–b), as visualized by confocal fluorescence microscope. </plain></SENT>
<SENT sid="84" pm="."><plain>Total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> decrease was also confirmed by immunofluorescence staining (green, c–d). </plain></SENT>
<SENT sid="85" pm="."><plain>DAPI (blue) was used to counterstain cells either as merged (a–b) or unmerged images (e–f). C, staining of virus-infected cells with P3490 and <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibodies (as in A and B) was quantified by fluorescence plate reader, and normalized vs. DAPI to control for cell numbers. </plain></SENT>
<SENT sid="86" pm="."><plain>The decrease of P3490 (∼40%; *, p&lt;0.05, unpaired t-test) and total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(60%; p&lt;0.001, unpaired t-test) staining caused by <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> knockdown was calculated relative to cells infected with the control shRNA (arbitrarily set as 1). </plain></SENT>
<SENT sid="87" pm="."><plain>Error bars represent the standard error of the mean (SEM). </plain></SENT>
<SENT sid="88" pm="."><plain>Data are mean ± SEM of three independent experiments. D, HEK293 cells were transiently transfected with <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-tagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt, S137A or S137D), treated with 50 µM hydroxyfasudil for 16 hr, and double stained with an anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> (red) and P3490 (green) antibodies. </plain></SENT>
<SENT sid="89" pm="."><plain>Only cells expressing the phosphomimetic <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) stained positive with P3490 (g–i), but not <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt) (a–c) or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A) (d–f). </plain></SENT>
<SENT sid="90" pm="."><plain>Arrowheads indicate two cells that expressed <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) and stained positive with P3490. E, Western blot confirmed comparable levels of <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> over-expression (wt, S137A and S137D) in transiently transfected HEK293 cells, as compared to cells transfected with an empty vector (pcDNA3). F, cells transfected (as in E) with pcDNA3 or various <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> constructs were immunostained with P3490, and quantified on a fluorescence plate reader with normalization vs. DAPI. </plain></SENT>
<SENT sid="91" pm="."><plain>The effects of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> over-expression on P3490 staining are represented as relative change compared to cells transfected with pcDNA3. </plain></SENT>
<SENT sid="92" pm="."><plain>Only <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) increased P3490 staining (***, p&lt;0.001, unpaired t-test). </plain></SENT>
<SENT sid="93" pm="."><plain>Cells were not treated with hydroxyfasudil. </plain></SENT>
<SENT sid="94" pm="."><plain>Error bars represent the SEM. </plain></SENT>
<SENT sid="95" pm="."><plain>Data are mean ± SEM of three independent experiments. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0032802.g002"/></fig></SecTag></sec><sec id="s2b"><title><text><SENT sid="96" pm="."><plain><z:uniprot sup="inside" fb="121" ids="Q9NJE9">Phosphatase</z:uniprot> inhibitors increase pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels in cultured cells </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>To identify candidate <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot> for pSer-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, we employed pharmacologic inhibitors of serine/threonine <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot> in cultured cells. </plain></SENT>
<SENT sid="98" pm="."><plain>Okadaic acid (OA) inhibits the serine/threonine-specific <z:uniprot sup="inside" fb="2" ids="Q9QSP3,Q8JTH2,Q2Y2M5,Q6X1D7,P0C798,P0C799,Q9E787,P33454,P06940,P16380,A7WNB2,O56774,A4UHP9,A4UHQ4,O55778,Q82037,Q8B9Q8,P14156,P24567,P03421,O42062,P12579,Q08454,Q82681,Q5VKP5,Q5K2K6,Q6X1D3,O56773,P35974,Q9WMB4,P03422,P26033,Q00793,Q6E0X0,P0C569,Q5MKM7,P19717,P16072,P16595,P60166,Q9JGU0,P16073,P24698,Q9DLD6,Q06427,Q9IK91,Q83956,P35939,P32530,P28054,P32531,P32532,P23055,P23056,P06163,P06162,P22044,P21738,Q01769,P11208,P15198,Q66T64,P22363,Q0GBX8,P69479,Q8B6J8,A3RM20,P69480,Q9IPJ8,P06747,Q0GBY3,P16286,P35945,Q03335,O70790,P14251,Q9DUE2,P14252,P04859,O57285,P04860,Q9QJT8,Q86606,Q91DS2,P21299,Q5GA89,D8V071,Q9WS39,Q4VKV7,P03520,Q8B0H3,P04879,P04880,Q8B0I3,Q8B0H8,P04878,P04877,Q5VKP1,Q9E7N7">phosphoprotein</z:uniprot> <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> (PPP) family, in particular its two most abundant members, <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> [15]. </plain></SENT>
<SENT sid="99" pm="."><plain>Differential potencies of OA towards its target <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot> have enabled its use to implicate candidates, particularly <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (IC50∼15–50 nM) and <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (IC50∼0.1–0.3 nM) [16]. </plain></SENT>
<SENT sid="100" pm="."><plain>Thus, we treated HEK293 cells with increasing concentrations of OA, and tested the effects on pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels by immunostaining with P3490. </plain></SENT>
<SENT sid="101" pm="."><plain>16 hr of OA treatment markedly increased the number of P3490-positive cells at mid-nanomolar concentrations (≥10 nM), which was evident both microscopically (Fig. 3A) and after quantification using a fluorescence plate reader (Fig. 3B). </plain></SENT>
<SENT sid="102" pm="."><plain>The effective concentration of OA to increase pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels was much higher than its IC50 for <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (0.1–0.3 nM), and more consistent with its known IC50 for <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (15–50 nM). </plain></SENT>
<SENT sid="103" pm="."><plain>We also used endothall, a structurally distinct <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> inhibitor that is also much more potent against <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (IC50 = 90 nM) than <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (IC50 = 5 µM) [17], [18]. </plain></SENT>
<SENT sid="104" pm="."><plain>Like OA, endothall increased P3490 staining at concentrations (mid-micromolar) that are substantially higher than its IC50 for <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot>, but similar to that for <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (Fig. 3A and 3B). </plain></SENT>
<SENT sid="105" pm="."><plain>Due to cytotoxic effects at high concentrations, we were unable to carry out complete dose-responses of OA and endothall with regard to pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. </plain></SENT>
<SENT sid="106" pm="."><plain>At their effective concentrations, neither drug affected the total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels within cells (Fig. 3C). </plain></SENT>
<SENT sid="107" pm="."><plain>Fostriecin, a highly specific and potent inhibitor of <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (IC50 for <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> = 1.5–5.5 nM; IC50 for <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> = 45–58 µM), had no effect on P3490 staining, even at 1 µM (data not shown), a concentration expected to fully inhibit <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> in a living cell [16]. </plain></SENT>
<SENT sid="108" pm="."><plain>Taken together, these results suggested that <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>, rather than <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot>, might be responsible for dephosphorylation of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0032802-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032802.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="109" pm="."><plain>Pharmacologic inhibition of serine/threonine <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot> increases pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in cultured cells. </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>A, HEK293 cells were treated with okadaic acid (OA) (a–d) or endothall (e–h) for 16 hr at increasing concentrations (1, 3 and 10 nM for OA; 1, 3 and 10 µM for endothall), followed by immunostaining with P3490 (green) and counterstaining with DAPI (blue). </plain></SENT>
<SENT sid="111" pm="."><plain>The number of P3490-positive cells and overall P3490 staining intensity increased notably at 10 nM of OA and 10 µM of endothall treatment. B, effects of OA and endothall on P3490 staining were quantified using a fluorescence plate reader. </plain></SENT>
<SENT sid="112" pm="."><plain>P3490 levels were normalized vs. DAPI, and the effects of the drugs were represented as relative change vs. the vehicle controls. </plain></SENT>
<SENT sid="113" pm="."><plain>OA and endothall increased P3490 staining dose-dependently. </plain></SENT>
<SENT sid="114" pm="."><plain>Error bars represent the SEM. </plain></SENT>
<SENT sid="115" pm="."><plain>Data are mean ± SEM of three independent experiments. C, HEK293 cells treated with 10 nM OA (a–b) or 10 µM endothall (c–d) were immunostained for total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (green) and counterstained with DAPI (blue). </plain></SENT>
<SENT sid="116" pm="."><plain>Merged images showed no changes in total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels as a result of the drugs. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0032802.g003"/></fig></SecTag></sec><sec id="s2c"><title><text><SENT sid="117" pm="."><plain>Genetic modulation of <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> activity controls pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels in cultured cells </plain></SENT>
</text></title><p><text><SENT sid="118" pm="."><plain>The above effects of <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> inhibitors indicated a role of <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> in pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> dephosphorylation. </plain></SENT>
<SENT sid="119" pm="."><plain>To test this more definitively, we knocked down the alpha isoform of the <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> catalytic subunit, PP1Cα, by transfecting HEK293 cells with siRNAs. </plain></SENT>
<SENT sid="120" pm="."><plain>In parallel, we also knocked down the alpha isoform of the <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> catalytic subunit, PP2ACα. </plain></SENT>
<SENT sid="121" pm="."><plain>Based on Western blot analysis, endogenous PP1Cα and PP2ACα were both knocked down by 90% with no effect on cellular <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels (Fig. 4C). </plain></SENT>
<SENT sid="122" pm="."><plain>This was also confirmed via immunofluorescence staining of the transfected cells (Fig. 4A). </plain></SENT>
<SENT sid="123" pm="."><plain>We detected a three-fold increase of P3490 staining in cells transfected with the PP1Cα-specific siRNA in comparison to those transfected with the control siRNA (Fig. 4A and B). </plain></SENT>
<SENT sid="124" pm="."><plain>In contrast, silencing PP2ACα had no effect on P3490 staining (Fig. 4A and B). </plain></SENT>
<SENT sid="125" pm="."><plain>As an additional test, in HeLa cells we over-expressed wild-type PP1Cα, a catalytically inactive PP1Cα(H125A) mutant, or wild-type PP2ACα, and stained with P3490. </plain></SENT>
<SENT sid="126" pm="."><plain>Nearly all cells expressing wild type PP1Cα stained negative for pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, while many cells expressing the inactive PP1Cα(H125A) mutant or wild type PP2ACα stained positive for pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (Fig. 4D). </plain></SENT>
<SENT sid="127" pm="."><plain>These data strongly suggested that <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> dephosphorylates <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0032802-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032802.g004</object-id><label>Figure 4</label><caption><title><text><SENT sid="128" pm="."><plain>Protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot>-1 (<z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>) dephosphorylates <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137. </plain></SENT>
</text></title><p><text><SENT sid="129" pm="."><plain>A, HEK293 cells were transfected with control, or sequence-specific siRNAs targeting human PP1Cα or PP2ACα. </plain></SENT>
<SENT sid="130" pm="."><plain>They were immunostained with P3490 (a–c) or the antibody against total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (d–f) (both in green) and counterstained with DAPI (blue). </plain></SENT>
<SENT sid="131" pm="."><plain>Silencing PP1Cα, but not PP2ACα, increased the number of P3490-positive cells and their staining intensities, while having no effect on total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. B, effects of PP1Cα and PP2ACα knockdown on P3490 staining were quantified using the fluorescence plate reader, normalized vs. DAPI, and represented as change relative to control siRNA. </plain></SENT>
<SENT sid="132" pm="."><plain>PP1Cα knockdown increased P3490 staining three-fold (***, p&lt;0.001, unpaired t-test), while PP2ACα knockdown had no effect. </plain></SENT>
<SENT sid="133" pm="."><plain>Error bars represent the SEM. </plain></SENT>
<SENT sid="134" pm="."><plain>Data are mean ± S.E.M. of three independent experiments. C, Western blot confirmed &gt;90% knockdown of both PP1Cα and PP2ACα in HEK293 cells. </plain></SENT>
<SENT sid="135" pm="."><plain>Neither affected <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels. </plain></SENT>
<SENT sid="136" pm="."><plain>Arrowhead indicates PP1Cα. </plain></SENT>
<SENT sid="137" pm="."><plain>The identity of the protein band above PP1Cα, which cross-reacts with PP1Cα antibody, is unknown. D, HeLa cells were transfected with <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα(wt) (a–c), <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα(H125A) (catalytically inactive) (d–f) or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP2ACα (g–i), double immunolabeled with an anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody (red) and P3490 (green), and counterstained with DAPI (blue). </plain></SENT>
<SENT sid="138" pm="."><plain>Neither <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα(H125A) nor <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP2ACα over-expression affected P3490 staining of the transfected cells (as indicated by the presence of cells that were both red and green). </plain></SENT>
<SENT sid="139" pm="."><plain>However, PP1Cα(wt) over-expression inhibited P3490 staining (as indicated by the mutual exclusivity of red and green cells). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0032802.g004"/></fig></SecTag></sec><sec id="s2d"><title><text><SENT sid="140" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> interacts with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in a pS137-dependent manner </plain></SENT>
</text></title><p><text><SENT sid="141" pm="."><plain>The preceding experiments correlated <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> activity with pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> dephosphorylation, but left uncertain whether the dephosphorylation is carried out directly by <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>, or by an unknown <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> whose activity is regulated by <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>. </plain></SENT>
<SENT sid="142" pm="."><plain>To test this, we transiently expressed <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα and <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in HEK293 cells, immunoprecipitated <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα via an anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody, and tested for co-precipitation of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="143" pm="."><plain><z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP2ACα was separately co-expressed with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> and immunoprecipitated as a control. </plain></SENT>
<SENT sid="144" pm="."><plain>We readily detected <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in a complex with PP1Cα, but not PP2ACα (Fig. 5A). </plain></SENT>
<SENT sid="145" pm="."><plain>We next tested for preferential binding of PP1Cα to pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> vs. unphosphorylated <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> by using the phosphomimetic <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) vs. phospho-resistant <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A) mutant. </plain></SENT>
<SENT sid="146" pm="."><plain>We transiently expressed HA-tagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt), <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A) or <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) in HEK293 cells along with <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα, followed by immunoprecipitation of <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα and Western blot for co-precipitation of HA-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="147" pm="."><plain>PP1Cα bound more phosphomimetic <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) and less phospho-resistant <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A) in comparison to <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt), with all <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> variants expressed at a similar level (Fig. 5B). </plain></SENT>
<SENT sid="148" pm="."><plain>These data suggested that Ser-137 phosphorylation promotes <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> interaction with <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>, which subsequently dephosphorylates pSer-137. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0032802-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032802.g005</object-id><label>Figure 5</label><caption><title><text><SENT sid="149" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> interact in cultured cells. </plain></SENT>
</text></title><p><text><SENT sid="150" pm="."><plain>A, HEK293 cells were co-transfected with an untagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> along with either an empty vector (pcDNA3) (Lane 1), or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-tagged PP1Cα (Lane 2), or PP2ACα (Lane 3), followed by immunoprecipitation with an anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody and Western blot for <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="151" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> co-immunoprecipitated specifically with PP1Cα, but not PP2ACα. B, HA-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> constructs (wt, S137A or S137D) were co-transfected into HEK293 cells with pcDNA3 (Lanes 1–3) or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα (Lanes 4–6). </plain></SENT>
<SENT sid="152" pm="."><plain><z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα was immunoprecipitated with an anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody, and co-immunoprecipitated HA-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> was detected by an anti-HA antibody. </plain></SENT>
<SENT sid="153" pm="."><plain>Relative to <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt), more <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137D) and less <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(S137A) bound to PP1Cα. C, Purified 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (wt, S137A or S137D) proteins were bound to Ni-NTA beads, and subsequently mixed with recombinant PP1Cα (Lanes 2–4). </plain></SENT>
<SENT sid="154" pm="."><plain>Beads without His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> were mixed with the same amount of PP1Cα to control for nonspecific binding (Lane 1). </plain></SENT>
<SENT sid="155" pm="."><plain>Beads were washed, and analyzed for binding of PP1Cα to 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> by Western blot. </plain></SENT>
<SENT sid="156" pm="."><plain>6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> proteins were visualized by Coomassie blue staining. </plain></SENT>
<SENT sid="157" pm="."><plain>No specific binding was observed between purified PP1Cα and 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (wt, S137A or S137D), despite that they were abundantly present. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0032802.g005"/></fig></SecTag><p><text><SENT sid="158" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> is known to interact directly with a small number of substrates [19]. </plain></SENT>
<SENT sid="159" pm="."><plain>To determine if <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> directly binds <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, we tested for their binding in vitro. </plain></SENT>
<SENT sid="160" pm="."><plain>We immobilized recombinant 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (wt, S137A or S137D) proteins on nickel beads, mixed them with bacterially expressed recombinant PP1Cα, and subsequently tested for their interaction via Western blot against PP1Cα. </plain></SENT>
<SENT sid="161" pm="."><plain>We did not detect any specific binding of PP1Cα to all three forms of 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt, S137A and S137D), despite that all proteins were abundantly present (Fig. 5C). </plain></SENT>
<SENT sid="162" pm="."><plain>Thus, our data suggest that <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> indirectly associates with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> through an unknown linker protein, and dephosphorylates pSer-137. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="163" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="164" pm="."><plain>Our prior studies were the first to demonstrate how <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s biological activities are regulated, at least in part, through phosphorylation at Ser-137 by the Rho-associated kinase ROCK. </plain></SENT>
<SENT sid="165" pm="."><plain>Ser-137 phosphorylation abolishes <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s binding to polyproline-containing ligands, e.g. <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot>, which reduces its ability to inhibit polyglutamine-dependent <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot> aggregation [6]. </plain></SENT>
<SENT sid="166" pm="."><plain>Our current work identifies <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> as the principal <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> to dephosphorylate <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> at Ser-137. </plain></SENT>
<SENT sid="167" pm="."><plain>By using a phospho-antibody against pSer-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, we found that pharmacologic inhibition and genetic knockdown of the catalytic subunit of <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> (PP1Cα), but not <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> (PP2ACα), increased pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> levels in cultured cells. </plain></SENT>
<SENT sid="168" pm="."><plain>PP1Cα binds <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> in cultured cells. </plain></SENT>
<SENT sid="169" pm="."><plain>This interaction increases when Ser-137 is mutated to aspartate, mimicking phosphorylation, and decreases when it is mutated to alanine, blocking phosphorylation. </plain></SENT>
<SENT sid="170" pm="."><plain>The simplest interpretation of our data is that <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> directly dephosphorylates pSer-137 of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> is a major eukaryotic serine/threonine <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot>, and is thought to catalyze the majority of cellular protein dephosphorylation events [19]. </plain></SENT>
<SENT sid="172" pm="."><plain>There are four different catalytic subunits of <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> in mammals (α, β, γ1,γ2), which are associated with a large number of regulatory subunits. </plain></SENT>
<SENT sid="173" pm="."><plain>This allows for hundreds of dimeric holoenzymes that are highly substrate-specific [19], [20], [21]. </plain></SENT>
<SENT sid="174" pm="."><plain>Our finding that <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> co-immunoprecipitates with <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> from cultured cells in a phosphorylation-dependent manner suggests that they co-exist in a complex to dephosphorylate pSer-137. </plain></SENT>
<SENT sid="175" pm="."><plain>However, a lack of direct binding between these two proteins in vitro suggests that they are likely linked in vivo by an unknown <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>-interacting protein (PIP). </plain></SENT>
<SENT sid="176" pm="."><plain>This is consistent with the fact that <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> lacks a typical <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>-docking motif (RVxF, SILK or MyPhoNE (myosin <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> N-terminal element with the consensus sequence of RxxQV/I/LK/RxY/W)) that is found in most PIPs [19]. </plain></SENT>
<SENT sid="177" pm="."><plain>Given the vast number of PIPs estimated to be encoded by the human genome (∼650, 180 of which are known) [19], identifying the one specifically targeting <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> to <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> could be a daunting task. </plain></SENT>
<SENT sid="178" pm="."><plain>However, screening <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-binding proteins for this PIP might be a more feasible approach. </plain></SENT>
<SENT sid="179" pm="."><plain>Our finding that mimicking Ser-137 phosphorylation (which should disrupt <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s binding to all polyproline-containing proteins) increases <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s interaction with <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> argues against this PIP being a polyproline-containing ligand of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
<SENT sid="180" pm="."><plain>This effectively rules out the vast majority of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>-interacting proteins as the candidate, and focuses our future efforts on the limited number of non-polyproline ligands of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (e.g. <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9PW38,Q54KM0,Q9NQX3,Q8BUV3,Q03555">gephyrin</z:uniprot>) [3]. </plain></SENT>
<SENT sid="181" pm="."><plain>At a minimum, this will reveal the additional linker protein, if existent, between <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> and the unknown PIP, and take us one step closer to identifying it. </plain></SENT>
</text></p><p><text><SENT sid="182" pm="."><plain>As an essential protein for all eukaryotic cells, <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> has now been linked to several human diseases such as Huntington disease [6] and cancer [7], [8], [9], [10], [11], [12]. </plain></SENT>
<SENT sid="183" pm="."><plain>It will thus be of great interest to identify therapeutic approaches to regulate its activity. </plain></SENT>
<SENT sid="184" pm="."><plain>Our prior and current identification of ROCK and <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> as direct regulators of Ser-137 phosphorylation and dephosphorylation raises the possibility of targeting these two enzymes to manipulate <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> activity and treat these diseases. </plain></SENT>
<SENT sid="185" pm="."><plain>For example, ROCK inhibitors (e.g. fasudil), which are expected to up-regulate <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> activity, are already in clinical use to reduce vasospasm in the setting of subarachnoid hemorrhage [22], [23]. </plain></SENT>
<SENT sid="186" pm="."><plain>Importantly, they ameliorate behavioral deficits of HD transgenic mice [24] and have been validated as being anti-metastatic in several cancer models [25], [26], [27], [28]. </plain></SENT>
<SENT sid="187" pm="."><plain>Our work thus represents an early step in defining the mechanisms by which it may be possible to specifically control <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>'s activity to benefit patients. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s4"><title><text><SENT sid="188" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s4a"><title><text><SENT sid="189" pm="."><plain>Plasmids </plain></SENT>
</text></title><p><text><SENT sid="190" pm="."><plain>Mammalian expression vectors encoding <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα (wt or H125A) and <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP2ACα were kindly provided by Dr. Hiroshi Shima (Miyagi Cancer Center Research Institute, Japan) [29]. </plain></SENT>
<SENT sid="191" pm="."><plain>Mammalian expression vectors encoding untagged or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-tagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (wt, S137A and S137D) were cloned in pcDNA3 as described previously [6]. </plain></SENT>
<SENT sid="192" pm="."><plain>HA-tagged human <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (wt, S137A and S137D) was PCR amplified and cloned into the EcoRI (5′) and XhoI (3′) sites of pcDNA3.1. </plain></SENT>
<SENT sid="193" pm="."><plain>Primer sequences are as follows: 5′-CCGGAATTCGCCGCCATGGCCTACCCATATGATGTTCCAGATTACGCTTCTTTGGGTGCCGGGTGGAACGCCTACATCGACAACCTCATG-3′ (upper primer containing an HA-tag); 5′-CCGCCGCTCGAGTCAGTACTGGGAACGCCGAAGGTGG-3′ (lower primer). </plain></SENT>
</text></p></sec><sec id="s4b"><title><text><SENT sid="194" pm="."><plain>siRNAs and shRNAs </plain></SENT>
</text></title><p><text><SENT sid="195" pm="."><plain>Negative control siRNA (SI03650325) and human PP1Cα-specific siRNA (SI02225748) were purchased from Qiagen. </plain></SENT>
<SENT sid="196" pm="."><plain>A pool of three siRNAs targeting different regions of human PP2ACα were purchased from Santa Cruz (sc-43509). </plain></SENT>
<SENT sid="197" pm="."><plain>To silence <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>, a 21nt sequence (5′-GGAATTTAGCATGGATCTTCG-3′) was custom-designed to target 246-267nt of human <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> mRNA, and cloned as short hairpin RNA (shRNA) downstream of the U6 promoter in a lentiviral vector, pFLRu-FH (kind gift of Dr. Greg Longmore) [30]. </plain></SENT>
<SENT sid="198" pm="."><plain>A control shRNA was similarly constructed using a non-targeting sequence (5′-CAACAAGATGAAGAGCACCAA-3′) adapted from the MISSION Non-Target shRNA control vector from Sigma. </plain></SENT>
<SENT sid="199" pm="."><plain>Lentiviral particles were purified by the Hope Center Viral Vectors Core at Washington University. </plain></SENT>
</text></p></sec><sec id="s4c"><title><text><SENT sid="200" pm="."><plain>Antibodies </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>Commercially available primary antibodies were as follows: rabbit anti-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (Cell Signaling, #3237), mouse anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> tag (Santa Cruz, sc-40), rabbit anti-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> (Santa Cruz, sc-1616-R), rabbit anti-PP1Cα (Cell Signaling, #2582), rabbit anti-PP2ACα (Cell Signaling, #2038), mouse anti-HA tag (Covance, MMS-101P). </plain></SENT>
<SENT sid="202" pm="."><plain>Custom-made antibodies include rabbit polyclonal antibody against the C-terminus of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (KCYEMASHLRRSQY, gift of Dr. Nicholas A. </plain></SENT>
<SENT sid="203" pm="."><plain>DiProspero) and affinity purified rabbit polyclonal anti-pS137-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (New England Peptides, Ac-CMASHLRR(pS)QY-OH) [6]. </plain></SENT>
<SENT sid="204" pm="."><plain>Secondary antibodies used for Western blotting include <z:uniprot sup="inside" fb="0" ids="P86348,P81800,P00634,P21948,P83456,Q05205,O60109,P19147">alkaline phosphatase</z:uniprot>-conjugated secondary antibodies (Sigma, A3562) and horseradish <z:uniprot sup="inside" fb="71" ids="Q55080,Q05855,Q01603,B3EWG7,P16147,P15984,P28313,A8NK72,P28314,P84714,P85317,P85957,Q9SCX8">peroxidase</z:uniprot>-conjugated secondary antibodies (Amersham Biosciences, NA9340V for anti-rabbit and NA931V for anti-mouse antibodies). </plain></SENT>
<SENT sid="205" pm="."><plain>Secondary antibodies for immunofluorescence staining include Alexa Fluor® 488-conjugated goat anti-rabbit IgG (Invitrogen, A-11034) and Alexa Fluor® 546-conjugated goat anti-mouse IgG (Invitrogen, A-11030). </plain></SENT>
<SENT sid="206" pm="."><plain>Agarose conjugated with secondary anti-mouse IgG (A6531) and EZview Red affinity gel conjugated with rabbit anti-<z:uniprot sup="inside" fb="0" ids="Q17103">c-Myc</z:uniprot> antibody (E6654) were purchased from Sigma. </plain></SENT>
</text></p></sec><sec id="s4d"><title><text><SENT sid="207" pm="."><plain>Reagents </plain></SENT>
</text></title><p><text><SENT sid="208" pm="."><plain>Alpha isoform of bacterially expressed recombinant <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> catalytic subunit was purchase from Sigma (P7937). </plain></SENT>
<SENT sid="209" pm="."><plain>Nickel-NTA beads were purchased from Qiagen (30410). </plain></SENT>
<SENT sid="210" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P84885,P26228,P43131,P61153,P0DM47">Protease inhibitor</z:uniprot> cocktail (11-836-170-001) was purchased from Roche Diagnostics. </plain></SENT>
<SENT sid="211" pm="."><plain><z:uniprot sup="inside" fb="27" ids="P55797,P83410">ECL</z:uniprot> Plus Western blotting detection kit (RPN2132) was purchased from GE Healthcare. </plain></SENT>
<SENT sid="212" pm="."><plain>Lysophosphatidic acid (L7260) was purchased from Sigma. </plain></SENT>
<SENT sid="213" pm="."><plain>Okadaic acid (495609), Endothall (324760), Fostriecin (344280) and Hydroxyfasudil (390602) were purchased from Calbiochem. </plain></SENT>
<SENT sid="214" pm="."><plain>Fetal bovine serum (SH3007103) was purchased from Hyclone. </plain></SENT>
<SENT sid="215" pm="."><plain>Gold anti-fade mounting media was purchased from Invitrogen (P36934). </plain></SENT>
</text></p></sec><sec id="s4e"><title><text><SENT sid="216" pm="."><plain>Cell culture and transfection </plain></SENT>
</text></title><p><text><SENT sid="217" pm="."><plain>HEK293, HeLa and NIH 3T3 cells were cultured in Dulbecco's modified Eagle medium containing 10% fetal bovine serum and penicillin/streptomycin. </plain></SENT>
<SENT sid="218" pm="."><plain>Lipofectamine 2000 (Invitrogen) was used for transfecting both DNAs and siRNAs using the protocol recommended by the manufacturer. </plain></SENT>
</text></p></sec><sec id="s4f"><title><text><SENT sid="219" pm="."><plain>Immunoprecipitation </plain></SENT>
</text></title><p><text><SENT sid="220" pm="."><plain>HEK293 cells over-expressing <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP1Cα(wt or H125A) or <z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot>-PP2ACα were lysed with buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Triton X-100, and <z:uniprot sup="inside" fb="0" ids="P80060">protease inhibitors</z:uniprot>. </plain></SENT>
<SENT sid="221" pm="."><plain>Cleared lysate was mixed with agarose beads bound with anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody. </plain></SENT>
<SENT sid="222" pm="."><plain>After 2 hr of mixing at 4°C, beads were washed 4 times with lysis buffer, and analyzed by Western blot for co-immunoprecitation of untagged or HA-tagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> via antibodies against <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (1∶1000) or the HA tag (1∶1000). </plain></SENT>
<SENT sid="223" pm="."><plain>For in vitro pull-down experiment, 20 µl nickel NTA beads were pre-blocked with 1% bovine <z:uniprot sup="inside" fb="0" ids="Q3T478,P02769,P49822,P85295,P19121,C0HJD2,C0HJC5,Q5XLE4,P49064,P35747,P02768,P21847,A2V9Z4,Q28522,O35090,A6YF56,P07724,P83517,P08835,Q5NVH5,P49065,P02770,P14639">serum albumin</z:uniprot> (BSA) for 30 min at room temperature, and subsequently mixed with 10 µg 6His-tagged <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>(wt, S137A and S137D) proteins previously purified from bacteria [6] for 30 min at 4°C. </plain></SENT>
<SENT sid="224" pm="."><plain>After washing, 2 µg of recombinant PP1Cα was added to the beads in 100 µl binding buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% BSA, 0.1% Triton X-100 and <z:uniprot sup="inside" fb="0" ids="P80060">protease inhibitors</z:uniprot>. </plain></SENT>
<SENT sid="225" pm="."><plain>Following 1 hr incubation at 4°C, beads were washed 4 times with binding buffer without BSA, and analyzed by Western blot for PP1Cα or Coomassie blue staining for 6His-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot>. </plain></SENT>
</text></p></sec><sec id="s4g"><title><text><SENT sid="226" pm="."><plain>Immunofluorescence staining </plain></SENT>
</text></title><p><text><SENT sid="227" pm="."><plain>Cultured cells were fixed for 30 min with 4% paraformaldehyde, washed 3 times with PBS, followed by blocking with 2% BSA in PBS/0.1% Triton X-100 for 30 min. </plain></SENT>
<SENT sid="228" pm="."><plain>P3490 antibody was diluted at 1∶5000 (v/v) with blocking buffer and incubated with cells for 2 hr at room temperature or overnight at 4°C. </plain></SENT>
<SENT sid="229" pm="."><plain>Cells were washed 4 times with PBS/0.1% Triton X-100, incubated with 1∶500 dilution of Alexa Fluor® 488 goat anti-rabbit secondary antibody in blocking buffer for 2 hr at room temperature, washed 4 times with PBS/0.1% Triton X-100, and mounted. </plain></SENT>
<SENT sid="230" pm="."><plain>For total <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> staining, custom-made rabbit polyclonal antibody against the C-terminus of <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> (KCYEMASHLRRSQY) was used at 1∶100 and followed by secondary antibody incubation as for P3490. </plain></SENT>
<SENT sid="231" pm="."><plain>For double labeling, cells were simultaneously incubated with P3490 (1∶5000) and anti-<z:uniprot sup="inside" fb="92" ids="Q9W4S7,P01108,P09416">Myc</z:uniprot> antibody (1∶1000) overnight at 4°C, followed by 2 hr incubation with 1∶500 dilution of Alexa Fluor® 488 goat anti-rabbit antibody and Alexa Fluor® 546 goat anti-mouse antibodies at room temperature. </plain></SENT>
<SENT sid="232" pm="."><plain>In all cases, DAPI was included in the secondary antibody solution at a concentration of 1 µg/ml. </plain></SENT>
<SENT sid="233" pm="."><plain>Images were acquired using the Zeiss LSM 5 PASCAL system equipped with the following lasers: 405 nm, 488 nm, 543 nm. </plain></SENT>
</text></p><p><text><SENT sid="234" pm="."><plain>For quantitative immunostaining within 96-well plates, HEK293 cells were grown to approximately 90% confluence, fixed, blocked, stained with P3490 (1∶5000) or anti-<z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> antibody (1∶100) and Alexa Fluor® 488 goat anti-rabbit antibody (1∶500), and counterstained with DAPI as described above. </plain></SENT>
<SENT sid="235" pm="."><plain>Cells were washed 4 times with PBS/0.1% Triton X-100, left in 150 µl PBS, and quantified for fluorescence intensity (490/519 nm for Alexa Fluor® 488 and 365/439 nm for DAPI) using a fluorescence plate reader (INFINITE M1000, Tecan, Inc). </plain></SENT>
<SENT sid="236" pm="."><plain>Background fluorescence was acquired using cells stained only with the secondary antibody. </plain></SENT>
<SENT sid="237" pm="."><plain>Background subtracted fluorescence intensity for Alexa Fluor® 488, which represented P3490 reactivity, was then normalized against DAPI level to control for total cell number. </plain></SENT>
<SENT sid="238" pm="."><plain>For all experiments, at least 4 replicate wells were quantified for a given condition, and each experiment was repeated at least three times independently. </plain></SENT>
</text></p></sec><sec id="s4h"><title><text><SENT sid="239" pm="."><plain>Antigen competition </plain></SENT>
</text></title><p><text><SENT sid="240" pm="."><plain>P3490 was first diluted 1∶5000 in the blocking buffers for immunofluorescence (PBS/0.1% Triton X-100/2% BSA) or Western blot (TBS/0.05% Tween 20/5% skim milk), and then mixed at 1∶200 molar ratio (antibody/peptide) with <z:uniprot sup="inside" fb="0" ids="Q42449,P02584,P07737">PFN1</z:uniprot> peptides containing (Ac-CMASHLRR(pS)QY-OH) or lacking a phosphate on Ser-137 (Ac-CMASHLRRSQY-OH) for 30 min at room temperature. </plain></SENT>
<SENT sid="241" pm="."><plain>A control antibody solution was set up by mixing an equivalent volume of water (instead of peptides) with P3490. </plain></SENT>
<SENT sid="242" pm="."><plain>All antibody solutions (no peptide, S137-peptide and pS137-peptide) were subsequently used to immunostain or immunoblot HEK293 cells as described above. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="243" pm="."><plain>We thank Dr. Hiroshi Shima and Dr. Nobuhiro Tanuma (Miyagi Cancer Center Research Institute, Japan) for generously providing <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9XZE5,G5EGK8,P23696,Q9ZSE4,Q06009">PP2A</z:uniprot> constructs. </plain></SENT>
<SENT sid="244" pm="."><plain>We thank Dr. Greg Longmore and Dr. Yunfeng Feng (Washington University in St. Louis) for sharing the lentiviral shRNA vector pFLRu-FH. </plain></SENT>
<SENT sid="245" pm="."><plain>We also thank Dr. Nicholas A. </plain></SENT>
<SENT sid="246" pm="."><plain>DiProspero (Merck &amp; Co., Inc.) for generously providing the anti-<z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">profilin-1</z:uniprot> antibody. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="247" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="248" pm="."><plain>Funding: This work was supported by the American Cancer Society Institutional Research Grant (Dr. Shao, <ext-link ext-link-type="uri" xlink:href="http://www.cancer.org">www.cancer.org</ext-link>), the Muscular Dystrophy Association (Dr. Shao and Dr. Diamond, <ext-link ext-link-type="uri" xlink:href="http://www.mdausa.org">www.mdausa.org</ext-link>), National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) R01 NS50284 (Dr. Diamond). </plain></SENT>
<SENT sid="249" pm="."><plain>The Hope Center Viral Vectors Core is supported by a Neuroscience Blueprint Core grant (P30 NS057105) from NIH to Washington University. </plain></SENT>
<SENT sid="250" pm="."><plain>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0032802-Birbach1"><text><SENT sid="251" pm="."><plain>1 BirbachA 2008 Profilin, a multi-modal regulator of neuronal plasticity. Bioessays 30 994 1002 18798527 </plain></SENT>
</text></ref><ref id="pone.0032802-Schluter1"><text><SENT sid="252" pm="."><plain>2 SchluterKJockuschBMRothkegelM 1997 Profilins as regulators of <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> dynamics. Biochim Biophys Acta 1359 97 109 9409807 </plain></SENT>
</text></ref><ref id="pone.0032802-Witke1"><text><SENT sid="253" pm="."><plain>3 WitkeW 2004 The role of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> complexes in cell motility and other cellular processes. Trends Cell Biol 14 461 469 15308213 </plain></SENT>
</text></ref><ref id="pone.0032802-Bottcher1"><text><SENT sid="254" pm="."><plain>4 BottcherRTWiesnerSBraunAWimmerRBernaA 2009 Profilin 1 is required for abscission during late cytokinesis of chondrocytes. Embo J 28 1157 1169 19262563 </plain></SENT>
</text></ref><ref id="pone.0032802-Behnen1"><text><SENT sid="255" pm="."><plain>5 BehnenMMurkKKursulaPCappallo-ObermannHRothkegelM 2009 Testis-expressed <z:uniprot sup="inside" fb="0" ids="Q9FE63,P0DKE6,A4GDQ6,P0DKF4,A4GDR4,A4GDR9,A4GDS9,A4GDT1,A4GDT5,A4GDU2,A4GDU6,A4GE42,A4GE49,A4GE54,P0DKG0,A4GFC0,A4GFC3,Q64LH0,Q32PB1,Q21193,A4KA44,Q8T8M2,Q9M7N0,P60673,Q9SNW5,P35083,Q9XF42,Q9DAD6,O24282,M0RCP6,Q9ST98,P49234,O24171,A4GCR6,P0DKE0,P0DKE2">profilins 3</z:uniprot> and 4 show distinct functional characteristics and localize in the acroplaxome-manchette complex in spermatids. BMC Cell Biol 10 34 19419568 </plain></SENT>
</text></ref><ref id="pone.0032802-Shao1"><text><SENT sid="256" pm="."><plain>6 ShaoJWelchWJDiprosperoNADiamondMI 2008 Phosphorylation of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> by <z:uniprot sup="inside" fb="0" ids="Q8LES0,Q8MIT6,Q13464,P61584,O77819">ROCK1</z:uniprot> regulates polyglutamine aggregation. Mol Cell Biol 28 5196 5208 18573880 </plain></SENT>
</text></ref><ref id="pone.0032802-Janke1"><text><SENT sid="257" pm="."><plain>7 JankeJSchluterKJandrigBTheileMKolbleK 2000 Suppression of tumorigenicity in breast cancer cells by the microfilament protein <z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">profilin 1</z:uniprot>. J Exp Med 191 1675 1686 10811861 </plain></SENT>
</text></ref><ref id="pone.0032802-Wittenmayer1"><text><SENT sid="258" pm="."><plain>8 WittenmayerNJandrigBRothkegelMSchluterKArnoldW 2004 Tumor suppressor activity of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> requires a functional <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> binding site. Mol Biol Cell 15 1600 1608 14767055 </plain></SENT>
</text></ref><ref id="pone.0032802-Zou1"><text><SENT sid="259" pm="."><plain>9 ZouLJaramilloMWhaleyDWellsAPanchapakesaV 2007 Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 97 1361 1371 17940506 </plain></SENT>
</text></ref><ref id="pone.0032802-Zou2"><text><SENT sid="260" pm="."><plain>10 ZouLDingZRoyP 2010 Profilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation. J Cell Physiol 223 623 629 20143334 </plain></SENT>
</text></ref><ref id="pone.0032802-Roy1"><text><SENT sid="261" pm="."><plain>11 RoyPJacobsonK 2004 Overexpression of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> reduces the migration of invasive breast cancer cells. Cell Motil Cytoskeleton 57 84 95 14691948 </plain></SENT>
</text></ref><ref id="pone.0032802-Bae1"><text><SENT sid="262" pm="."><plain>12 BaeYHDingZZouLWellsAGertlerF 2009 Loss of <z:uniprot sup="inside" fb="0" ids="Q42449,P0DKE8,P0DKE9,P0DKF0,P0DKF2,P0DKF3,P0DKF5,P0DKF6,P0DKF7,A4GDR7,A4GDT3,A4GE38,A4GE45,Q64LH1,Q8H2C9,P25816,P02584,Q9XW16,A4KA39,P26199,O65812,P52184,P07737,Q9SNW7,P35081,Q9XF40,P62962,Q9XG85,P49231,P35079,P62963,O82572,Q41344,O65809,P41372,P49232,O24169,P0DKD0,P0DKD1,P0DKD2,P0DKD3,P0DKD4,P0DKD5,P0DKD6,P0DKD7,P0DKD8,P0DKD9,P0DKE1,A4GD55">profilin-1</z:uniprot> expression enhances breast cancer cell motility by <z:uniprot sup="inside" fb="38" ids="Q0QLE9">Ena</z:uniprot>/<z:uniprot sup="inside" fb="2" ids="Q2TA49,P50551,P50552,P70460">VASP</z:uniprot> proteins. J Cell Physiol 219 354 364 19115233 </plain></SENT>
</text></ref><ref id="pone.0032802-DaSilva1"><text><SENT sid="263" pm="."><plain>13 Da SilvaJSMedinaMZulianiCDi NardoAWitkeW 2003 RhoA/ROCK regulation of neuritogenesis via <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> IIa-mediated control of <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> stability. J Cell Biol 162 1267 1279 14517206 </plain></SENT>
</text></ref><ref id="pone.0032802-Sathish1"><text><SENT sid="264" pm="."><plain>14 SathishKPadmaBMunugalavadlaVBhargaviVRadhikaKV 2004 Phosphorylation of <z:uniprot sup="inside" fb="0" ids="P84177,P32006,C0HL99,Q94JN2,Q9XF37,Q6QEJ7,Q9SQI9,P85984,Q68HB4,Q8T938,Q9FUB8,Q8V2L6,Q775N7,P53696,Q93YI9,Q84V37,P18321,Q5EF31,Q5FX67,Q77DS0,Q80DT4,O04725,Q8SAE6,P25843,Q8JL78,P49230,P0C0Y3,O81982,P18320,Q941H7,O49894,Q8V4T7,Q94JN3,Q6QNF8,Q8L5D8,B8QYR5,Q8I2J4,P86294,C0HJX6,Q9XF39,Q8GSL5,Q8GT39,Q9XF38,Q6RZE1,P39825,Q9U0E6,P23412,Q26734,O57243,P68695,Q77TH1,Q76ZN5,P0DSW5,P0DSW6,P07274">profilin</z:uniprot> regulates its interaction with <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> and poly (L-proline). Cell Signal 16 589 596 14751544 </plain></SENT>
</text></ref><ref id="pone.0032802-Bialojan1"><text><SENT sid="265" pm="."><plain>15 BialojanCTakaiA 1988 Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot>. </plain></SENT>
<SENT sid="266" pm="."><plain>Specificity and kinetics. Biochem J 256 283 290 2851982 </plain></SENT>
</text></ref><ref id="pone.0032802-Swingle1"><text><SENT sid="267" pm="."><plain>16 SwingleMNiLHonkanenRE 2007 Small-molecule inhibitors of ser/thr protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatases</z:uniprot>: specificity, use and common forms of abuse. Methods Mol Biol 365 23 38 17200551 </plain></SENT>
</text></ref><ref id="pone.0032802-Li1"><text><SENT sid="268" pm="."><plain>17 LiYMCasidaJE 1992 Cantharidin-binding protein: identification as protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 2A. Proc Natl Acad Sci U S A 89 11867 11870 1334551 </plain></SENT>
</text></ref><ref id="pone.0032802-Yi1"><text><SENT sid="269" pm="."><plain>18 YiKDSimpkinsJW 2008 Protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 1, protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 2A, and calcineurin play a role in estrogen-mediated neuroprotection. Endocrinology 149 5235 5243 18566123 </plain></SENT>
</text></ref><ref id="pone.0032802-Bollen1"><text><SENT sid="270" pm="."><plain>19 BollenMPetiWRagusaMJBeullensM 2010 The extended <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> toolkit: designed to create specificity. Trends Biochem Sci 35 450 458 20399103 </plain></SENT>
</text></ref><ref id="pone.0032802-Cohen1"><text><SENT sid="271" pm="."><plain>20 CohenPT 2002 Protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 1–targeted in many directions. J Cell Sci 115 241 256 11839776 </plain></SENT>
</text></ref><ref id="pone.0032802-Bollen2"><text><SENT sid="272" pm="."><plain>21 BollenM 2001 Combinatorial control of protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot>-1. Trends Biochem Sci 26 426 431 11440854 </plain></SENT>
</text></ref><ref id="pone.0032802-Takanashi1"><text><SENT sid="273" pm="."><plain>22 TakanashiYIshidaTMeguroTKiwadaHZhangJH 2001 Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 48 894 900; discussion 900–891 11322450 </plain></SENT>
</text></ref><ref id="pone.0032802-Tachibana1"><text><SENT sid="274" pm="."><plain>23 TachibanaEHaradaTShibuyaMSaitoKTakayasuM 1999 Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 141 13 19 10071681 </plain></SENT>
</text></ref><ref id="pone.0032802-Li2"><text><SENT sid="275" pm="."><plain>24 LiMHuangYMaAALinEDiamondMI 2009 Y-27632 improves rotarod performance and reduces <z:uniprot sup="inside" fb="0" ids="P42858,P42859,P51111,P51112">huntingtin</z:uniprot> levels in R6/2 mice. Neurobiol Dis 36 413 420 19591939 </plain></SENT>
</text></ref><ref id="pone.0032802-Burthem1"><text><SENT sid="276" pm="."><plain>25 BurthemJRees-UnwinKMottramRAdamsJLucasGS 2007 The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo <z:uniprot sup="inside" fb="0" ids="Q28270,P28906">CD34</z:uniprot>(+) CML progenitor cells. Leukemia 21 1708 1714 17554385 </plain></SENT>
</text></ref><ref id="pone.0032802-Ying1"><text><SENT sid="277" pm="."><plain>26 YingHBirocSLLiWWAlickeBXuanJA 2006 The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5 2158 2164 16985048 </plain></SENT>
</text></ref><ref id="pone.0032802-Itoh1"><text><SENT sid="278" pm="."><plain>27 ItohKYoshiokaKAkedoHUehataMIshizakiT 1999 An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. <z:uniprot sup="inside" fb="121" ids="Q9R053">Nat</z:uniprot> Med 5 221 225 9930872 </plain></SENT>
</text></ref><ref id="pone.0032802-Sahai1"><text><SENT sid="279" pm="."><plain>28 SahaiEIshizakiTNarumiyaSTreismanR 1999 Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 9 136 145 10021386 </plain></SENT>
</text></ref><ref id="pone.0032802-Mitsuhashi1"><text><SENT sid="280" pm="."><plain>29 MitsuhashiSShimaHTanumaNMatsuuraNTakekawaM 2003 Usage of tautomycetin, a novel inhibitor of protein <z:uniprot sup="inside" fb="121" ids="Q9NJE9">phosphatase</z:uniprot> 1 (<z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot>), reveals that <z:uniprot sup="inside" fb="0" ids="P80074,P50391,Q61041,Q63447,P30366,P48487,P22198,P48488">PP1</z:uniprot> is a positive regulator of <z:uniprot sup="inside" fb="0" ids="Q61UC4,Q07292">Raf-1</z:uniprot> in vivo. J Biol Chem 278 82 88 12374792 </plain></SENT>
</text></ref><ref id="pone.0032802-Feng1"><text><SENT sid="281" pm="."><plain>30 FengYNieLThakurMDSuQChiZ 2010 A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi. Genomics Proteomics Bioinformatics 8 238 245 21382592 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
